anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: One of the major advantages of a minimally invasive microdiscectomy is that when CSF leak occurs, there is minimal anatomic dead space for ongoing leakage following removal of the tubular retractor. However, there are no published reports that address the safety and long-term outcomes of same-day discharge for CSF leak after tubular microdiscectomy.
METHODS: This is a retrospective compartive study of 30 patients with incidental durotomy during minimally invasive tubular microdiscectomy occurring between January 1, 2009 to August 31, 2023 at our institution.
RESULTS: There were 16 patients (53%) admitted to hospital and 14 (47%) patients discharged home the same day following CSF leak. There were no differences in patient demographics between the two groups at baseline. Twenty-nine out of 30 (97%) of the patients had onlay duraplasty, and one (3%) patient was repaired using sutures through the tubular retractor. None were converted to an open approach. The hospitalized group was kept on bed rest overnight or for 24 h. The discharge group was kept on best rest for 2 h or mobilized immediately after surgery. No patients in either group required readmission or revision surgery for CSF leak. The average length of admission for the hospitalized group was 2.4 ± 4.0 days.
CONCLUSION: Patients with CSF leak during minimally invasive tubular microdiscectomy can be safely discharged home the same day.
An artificial peptide having an amino acid sequence which corresponds to a naturally occurring amino acid sequence of an HIV comprising an epitope and which further has two cysteine residues located on each side of said epitope, and further having a sulphur bridge between said two cysteine residues, which has been formed by a chemical oxidation step, is described. Furthermore, an artificial antigen which reacts with antibodies induced by an HIV is described. Said antigen mainly consists of an artificial peptide according to the invention. Additionally, a method of detecting antibodies induced by an HIV in a sample of body fluid, wherein said sample is subjected to an immunoassay, especially ELISA, and wherein an artificial antigen according to the invention is used as a diagnostic antigen, is described. A diagnostic immunoassay kit for said method is also described. Finally, a vaccine composition comprising, as an immunizing component, at least one antigen according to the invention, is described.
Healthy subjects completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing. Otherwise, the healthy subjects received no intervention.
Baclofen has been shown to increase the incidence of omphaloceles (ventral hernias) in fetuses of rats given approximately 13 times the maximum dose recommended for human use, at a dose which caused significant reductions in food intake and weight gain in dams. This abnormality was not seen in mice or rabbits.

There was also an increased incidence of incomplete sternebral ossification in fetuses of rats given approximately 13 times the maximum recommended human dose, and an increased incidence of unossified phalangeal nuclei of forelimbs and hindlimbs in fetuses of rabbits given approximately 7 times the maximum recommended human dose. In mice, no teratogenic effects were observed, although reductions in mean fetal weight with consequent delays in skeletal ossification were present when dams were given 17 or 34 times the human daily dose. There are no studies in pregnant women. Baclofen should be used during pregnancy only if the benefit clearly justifies the potential risk to the fetus.
FIELD: virology. SUBSTANCE: method involves the use of strain S. domestica N 48 hybrid cells for isolation and cultivation of swine classic plague virus. Strain shows all properties that are typical for hybrid cells. Strain ensures to identify virus of swine classic plague and provides its preparing at titers 5.5-6.5 lg. Strain of intraspecies hybrid cells of S. domestica is tested at positive result at cultivation and diagnosis of swine classic plague. Strain can be used in biotechnology, virology, veterinary for virus isolation and cultivation. EFFECT: hybrid cell strain indicated above.
Systems and methods are provided for evaluating hearing health of a given user. An input audio signal is transformed into the frequency domain and a first and second hearing profile are applied to the input audio sample. The first hearing profile represents a healthy hearing standard and the second hearing profile is the given user's hearing profile. Using the hearing profiles, first and second perceptually relevant information (PRI) values are generated for the input audio sample. The first and second PRI values are analyzed against each other to generate a PRI index value for the given user, where the PRI index value is a hearing health index value for the given user. The given user's hearing profile may additionally be applied to differently processed audio samples to evaluate the amount of perceptual rescue offered by various digital signal processing algorithms.
PURPOSE: To obtain a novel compd. as an antidepressant and a drug for hypertension having high selectivity for α 1 -adrenergic receptor, as well as to obtain its enantiomer, diastereomer, epimer and acid adduct.  
     CONSTITUTION: A compd. expressed by formula I, its enantiomer and acid adduct are used. In formula I, R is a 1 to 6 C alkyl, a 3 to 8 C cycloalkyl, etc., R 1 , R 2  are each H, a 1 to 6 C alkyl or acyl, and the compd. is, for example, 4-(2-cyclopentyl-3,3,3-trifluoropropan-1-yl)-imidazole. The compd. is obtd. by the following method. An organo magnesium compd. expressed by formula II (X is a halogen) is made to react with trifluoro acetic acid or its sodium salt to produce a ketone expressed by formula III. The obtd. ketone is made to react with a phosphonoacetate compd. expressed by formula IV in the presence of a base. Then the obtd. compd. is subjected to catalytic hydrogenation by using a catalyst and then to hydrolysis to obtain an acid compd. The obtd. acid compd. is made to react with thionyl chloride, then treated with diazomethane, made to react with gaseous hydrogen chloride and then made to react with formamidine acetate. 
     COPYRIGHT: (C)1992,JPO
Gasdermin E (GSDME) has recently been identified as a critical executioner to mediate pyroptosis. While epidermal keratinocytes can initiate GSDME-mediated pyroptosis, the role of keratinocyte GSDME in psoriatic dermatitis remains poorly characterized. Through analysis of GEO datasets, we found elevated GSDME levels in psoriatic lesional skin. Additionally, GSDME levels correlated with both psoriasis severity and response to biologics treatments. Single-cell RNA sequencing (scRNA-seq) from a GEO dataset revealed GSDME upregulation in keratinocytes of psoriasis patients. In the imiquimod (IMQ)-induced psoriasis-like dermatitis mouse model, both full-length and cleaved forms of caspase-3 and GSDME were elevated in the epidermis. Abnormal proliferation and differentiation of keratinocytes and dermatitis were attenuated in Gsdme-/- mice and keratinocyte-specific Gsdme conditional knockout mice after IMQ stimulation. Exposure of keratinocytes to mixed cytokines (M5), mimicking psoriatic conditions, led to GSDME cleavage. Moreover, the interaction between GSDME-FL and p65 or c-jun was significantly increased after M5 stimulation. GSDME knockdown inhibited nuclear translocation of p65 and c-jun and decreased upregulation of psoriatic inflammatory mediators such as IL1β, CCL20, CXCL1, CXCL8, S100A8, and S100A9 in M5-challenged keratinocytes. In conclusion, GSDME in keratinocytes contributes to the pathogenesis and progression of psoriasis, potentially in a pyroptosis-independent manner by interacting and promoting translocation of p65 and c-jun. These findings suggest that keratinocyte GSDME could serve as a potential therapeutic target for psoriasis treatment.
<P>PROBLEM TO BE SOLVED: To provide compositions and methods for the therapy and diagnosis of cancer, such as prostate cancer, and to provide diagnostic methods.  <P>SOLUTION: The composition may comprise one or more prostate-specific proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, the therapeutic composition may contain antigen presenting cells that express the prostate-specific proteins, or T cells that are specific for cells expressing such proteins. Such compositions may be used, for example, for the prevention and treatment of disease such as prostate cancer. Detection of a prostate-specific protein in a sample, or mRNA encoding such a protein is also provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The rate of aging can be determined, among other factors, by the diet during childhood and adolescence. Many additives are currently added to food, including carrageenan (E-407), a thickener derived from red algae. Although the acceptable daily intake for carrageenan is periodically re-evaluated, children show the highest levels of exposure with unknown potential effects on the aging process and longevity. Therefore, the aim of the present study is to know the effects in young mice of carrageenan intake, at the maximum level exposure scenario surveyed in children, on the homeostatic (nervous and immune) systems, the redox-inflammatory state and the repercussion that this may have on the aging and longevity of the animals. Swiss mice of 2 months of age (equivalent to 8 years old children) were used and 4 experimental groups were created (N = 10 animals/group): females and males that ingested carrageenan (540 mg/kg of κ-carrageenan in 200 μL of drinking water by pipette tip administration) and control females and males that took 200 μL of water, daily for 15 days. After that time, a battery of behavioral tests was performed, and peritoneal leukocytes were extracted to assess different immune functions and their redox and inflammatory state. These tests were repeated when the mice reached adulthood (7 months) and old age (18 months). Fecal microbiota was analyzed at the same sampling times. The results showed that animals that ingested carrageenan presented elevated levels of anxiety, impaired immune function and increased oxidative-inflammatory stress, with these effects extending into adulthood and old age and leading to reduced longevity in these mice. Overall, observed microbiota changes were related more to the aging process than the carrageenan intake. In conclusion, the exposure to high doses of the food additive carrageenan in childhood may contribute to an impairment of homeostasis, and consequently of health, with an increased oxidative-inflammatory stress, which implies an accelerated aging process, leading to a lower longevity.
Exacerbation of gout following therapy with probenecid and colchicine may occur; in such cases additional colchicine or other appropriate therapy is advisable. 

Probenecid increases plasma concentrations of methotrexate in both animals and humans. In animal studies, increased methotrexate toxicity has been reported. If probenecid and colchicine is given with methotrexate, the dosage of methotrexate should be reduced and serum levels may need to be monitored.

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. The biphasic action of salicylates in the renal tubules accounts for the so-called “paradoxical effect” of uricosuric agents. In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred.

Rarely, severe allergic reactions and anaphylaxis have been reported with the use of probenecid and colchicine. Most of these have been reported to occur within several hours after readministration following prior usage of the drug.

The appearance of hypersensitivity reactions requires cessation of therapy with probenecid and colchicine.

Colchicine has been reported to adversely affect spermatogenesis in animals. Reversible azoospermia has been reported in one patient.
The efficacy of intramuscular ziprasidone in the management of agitated schizophrenic patients was established in two short-term, double-blind trials of schizophrenic subjects who were considered by the investigators to be “acutely agitated” and in need of IM antipsychotic medication. In addition, patients were required to have a score of 3 or more on at least 3 of the following items of the PANSS: anxiety, tension, hostility and excitement. Efficacy was evaluated by analysis of the area under the curve (AUC) of the Behavioural Activity Rating Scale (BARS) and Clinical Global Impression (CGI) severity rating. The BARS is a seven point scale with scores ranging from 1 (difficult or unable to rouse) to 7 (violent, requires restraint). Patients' scores on the BARS at baseline were mostly 5 (signs of overt activity [physical or verbal], calms down with instructions) and as determined by investigators, exhibited a degree of agitation that warranted intramuscular therapy. There were few patients with a rating higher than 5 on the BARS, as the most severely agitated patients were generally unable to provide informed consent for participation in premarketing clinical trials. 

Both studies compared higher doses of ziprasidone intramuscular with a 2 mg control dose. In one study, the higher dose was 20 mg, which could be given up to 4 times in the 24 hours of the study, at interdose intervals of no less than 4 hours. In the other study, the higher dose was 10 mg, which could be given up to 4 times in the 24 hours of the study, at interdose intervals of no less than 2 hours.  
The results of the intramuscular ziprasidone trials follow:

  1. In a one-day, double-blind, randomized trial (n=79) involving doses of ziprasidone intramuscular of 20 mg or 2 mg, up to QID, ziprasidone intramuscular 20 mg was statistically superior to ziprasidone intramuscular 2 mg, as assessed by AUC of the BARS at 0 to 4 hours, and by CGI severity at 4 hours and study endpoint.
  2. In another one-day, double-blind, randomized trial (n=117) involving doses of ziprasidone intramuscular of 10 mg or 2 mg, up to QID, ziprasidone intramuscular 10 mg was statistically superior to ziprasidone intramuscular 2 mg, as assessed by AUC of the BARS at 0 to 2 hours, but not by CGI severity.
Human immunodeficiency virus type 1 (HIV-1) infection is a life-threatening and serious disease that is of major public health interest around the world. Standard-of-care for the treatment of HIV infection involves the use of a combination of antiretroviral (ARV) drugs to suppress viral replication to below detectable limits, to increase CD4+ cell count, and to delay disease progression. Darunavir (DRV) is an inhibitor of the dimerization and of the catalytic activity of the HIV-1 protease. It selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus infected cells, thereby preventing the formation of mature infectious virus particles. Cobicistat (COBI) is a mechanism-based inhibitor (MBI) of the cytochrome P450 (CYP)3A subfamily. Inhibition of CYP3A mediated metabolism by COBI enhances the systemic exposure of CYP3A substrates, such as DRV, where bioavailability is limited and half-life is shortened by CYP3A-dependent metabolism. DRV/COBI FDC tablet formulation would overcome the difficulties of pediatric participants (greater than or equal to \[\>=\] 3 years and weighing \>=15 kilograms \[kg\] to less than \[\<\] 25 kg) might encounter in swallowing a whole or 2 halves of an oral, non-disintegrating tablet, hence helping children to better adhere to their HIV treatment. The study consists of a screening phase (up to 21 days) and an open-label administration phase of 1 day. Safety will be assessed by adverse events (AEs). The total duration of the study is up to 32 days.
A preparation method of sugar-reducing powder and medicine for reducing blood sugar is provided, wherein the components are all natural nutritious food. Has good taste, and can be used for preparing any palatable wheaten food. Clinical trials prove that the Chinese medicinal composition has obvious curative effects on patients with diabetes and other patients with hyperlipidemia, such as patients with hypertension, coronary heart disease, rectal cancer and other patients with food restriction. Is safe for healthy people to eat and has no side effect. Meanwhile, the functions of the pancreatic islets can be improved, and the body can be shaped to achieve the purposes of prevention and treatment. The raw materials are selected and proportioned reasonably. Is convenient for long-term eating and home production.
The experiment comprises eight sessions total. People that request to be in the experiment will first complete demographic and self-report clinical assessments. People that meet our eligibility criteria will be invited to participate in the study. In the first session, clinical assessment are administered to determine eligibility for the full study. In the second session, participants complete a functional magnetic resonance imaging (MRI) session in which they complete three different reward-based decision-making tasks. After the MRI session, participants are randomized into one of three parallel arms to receive five consecutive days of cross-frequency transcranial alternating current stimulation (CF-tACS) in either delta-beta, control-frequency (theta-gamma), or placebo (sham) CF-tACS. In the third through seventh session, participants receive 40 minutes of CF-tACS while completing goal-setting and action planning worksheets. Before the first session of CF-tACS (the third session overall) and the last session of CF-tACS (the seventh session overall), participants complete brief self-report clinical assessments. On the third and seventh session (the first and fifth day of CF-tACS), the participant will complete the reward-based decision-making tasks prior to stimulation while EEG is recorded. In these two sessions, resting-state EEG is acquired before and after stimulation. The first and fifth session of tACS (third and seventh session overall) will take approximately three hours to complete. The second through fourth session of tACS (fourth through sixth session overall) will take approximately one hour to complete. In the follow-up session, visit 8, (approximately two weeks after the end of the five-days of stimulation), participants return for an in-person session that includes self-report clinical assessments and EEG during the reward-based decision-making tasks.
Background: Delirium is a common neuropsychiatric syndrome without an FDA-approved treatment. Commonly used modalities show little improvement in outcomes; therefore, prevention efforts are imperative. Abnormalities in the sleep/wake cycle have been linked to delirium, and melatonin has been proposed to replace the hypothesized low levels of endogenous melatonin and restore sleep/wake cycle synchronization. Objectives: The primary objective of this study was to evaluate the association between melatonin, benzodiazepines (BZDs) or zolpidem (ZLP), and the use of as-needed antipsychotics and BZDs for delirium in noncritically ill adult patients. Methods: This was a multicenter retrospective cohort study of noncritically ill adult patients admitted to two separate health systems from August 2012 to December 2018 receiving either melatonin or nonmelatonin medications (ZLP or BZDs) for sleep. The coprimary endpoint was the proportion of patients receiving a pro re nata (PRN) antipsychotic or BZD 5 days from the patient's first dose of melatonin, BZD, or ZLP. Secondary outcomes included evaluation of the coprimary outcome in patients 65 years of age or older, total number of PRN antipsychotic and BZD doses, and length of stay. Results: Two hundred and twenty-five patients were included in the final analysis. Administration of BZD or ZLP was associated with a higher risk of subsequent BZD administration as compared with melatonin (OR 2.78, 95% CI 1.2-1.87) and ZLP (OR 2.78, 95% CI 1.25-6.17). BZD or ZLP had no impact on PRN antipsychotic use compared with melatonin (OR 1.09, 95% CI 0.51-2.35) and ZLP (OR 1.16, 95% CI 0.56-2.4). Conclusion: Melatonin use was found to be associated with a significant decrease in PRN BZD use in noncritically ill patients hospitalized on general floors; however, there was no observed association with overall PRN antipsychotic use. These results suggest that using melatonin may help decrease utilization of medications commonly used to manage delirium.
Estriol Capsules (daily) plus Copaxone injections (daily). Progestin capsules given for 2 weeks every 3 months to avoid unopposed estrogens.
All the performance of the 40 MS patients will be compared to 40 control subjects matched in age, gender and sociocultural level. Subjects with a history of neurological and psychiatric condition or substance abuse will be excluded from the study. Control subjects will receive an honorary as a token for their time.
PURPOSE: A pharmaceutical composition containing non-peptidyl polymer-insulin multimers for preventing or treating diabetes is provided to degrade the multimers into monomers and to develop a long-acting insulin formulation. CONSTITUTION: A non-peptidyl polymer-insulin multimer is formed of two or more non-peptidyl polymer-insulin conjugates using cobalt ions. The non-peptidyl polymer-insulin conjugates are formed by covalent bonding non-peptidyl polymers with an insulin A chain amino terminal, a B chain amino terminal, or a B chain 29th lysine. The non-peptidyl polymer is a biodegradable polymer, a lipid polymer, chitin, hyaluronic acid, or a combination thereof. The biodegradable polymer is polyethylene glycol. A reaction group of the non-peptidyl polymer is an aldehyde group, a propionic aldehyde group, a butyl aldehyde group, a maleimide group, or a succinimide derivative. A method for preparing the multimers comprises: a step of reacting non-peptidyl polymer-insulin conjugates with a solution containing cobalt ions. A pharmaceutical composition for preventing or treating diabetes contains the multimers as an active ingredient.
A water-in-oil-in-water (W/O/W) emulsion to be used in an antigen delivery system to induce rapid and long-lasting immunity among populations of livestock, birds, and fish. The external aqueous phase of the W/O/W emulsion contains a thixotropic inorganic salt, such as aluminum hydroxide or alum. The presence of the inorganic salt helps to elicit both a Th1 and a Th2 response from the subject's immune system, and the thixotropic properties of the salt stabilize the water-in-oil-in-water emulsion, thereby providing a longer vaccine shelf life. The antigen dose to be delivered to the subject may be contained in entirely in the internal aqueous phase. Alternatively, a first portion of the total antigen dose may be included in the internal aqueous phase and a second portion is included in the external aqueous phase. The incorporation of a portion of the antigen in the external aqueous phase triggers a more uniform immune response across a vaccinated population. The W/O/W based vaccines can be administered either by injection or orally.